Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Qualigen Therapeutics, Inc. (RTTR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 09/29/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/15/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"QUALIGEN THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE LOSS For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 REVENUES Net product sales $ 1,627,031 $ 1,430,534 $ 3,234,201 $ 2,152,563 Total revenues 1,627,031 1,430,534 3,234,201 2,152,563 EXPENSES Cost of product sales 1,016,542 1,099,677 2,281,368 1,928,524 General and administrative 2,665,849 2,660,857 4,380,283 5,559,608 Research and development 1,326,544 1,506,227 3,448,095 3,370,972 Sales and marketing 169,223 305,103 368,337 443,426 Total expenses 5,178,158 5,571,864 10,478,083 11,302,530 LOSS FROM OPERATIONS OTHER EXPENSE , NET Gain on change in fair value of warrant liabilities Interest expense , net 377,416 921,652 Loss on voluntary conversio..." |
|
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/04/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/26/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 07/07/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 05/19/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/15/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 05/05/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 04/24/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 02/13/2023 |
8-K
| Quarterly results |
| 01/20/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/10/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex Transcription Inhibitor for the Intended Indication of Pancreatic Cancer CARLSBAD, Calif., January 10, 2023 — Qualigen Therapeutics, Inc. , a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead drug candidate, QN-302, for the indication of Pancreatic Cancer. QN-302 is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells." |
|
| 01/06/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/30/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 12/22/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"COMMON STOCK PURCHASE WARRANT qualigen therapeutics, inc. Warrant Shares: 2,500,000 Initial Exercise Date: June 22, 2023 Issue Date: December 22, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, Alpha Capital Anstalt or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the six month anniversary of the Issue Date and on or prior to 5:00 p.m. on June 22, 2028 but not thereafter, to subscribe for and purchase from Qualigen Therapeutics, Inc., a Delaware corporation , up to 2,500,000 shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitaliz...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of December 21, 2022, between Qualigen Therapeutics, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows: AR...",
"8% SENIOR CONVERTIBLE DEBENTURE DUE DECEMBER 22, 2025 THIS 8% SENIOR CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued 8% Senior Convertible Debentures of Qualigen Therapeutics, Inc., a Delaware corporation , having its principal place of business at 2042 Corte de Nogal, Carlsbad, CA 92011, designated as its 8% Senior Convertible Debenture due December 22, 2025 . FOR VALUE RECEIVED, the Company promises to pay to Alpha Capital Anstalt or its registered assigns , or shall have paid pursuant to the terms hereunder, the principal sum of $3,300,000 on December 22, 2025 or such earlier date as this Debenture is required or permitted to be repaid as provided hereunder, and to pay interest to the Holder on the aggregate unconverted and then outstanding principal amoun...",
"Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:" |
|
| 12/12/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/22/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/28/2022 |
8-K
| Quarterly results |
| 10/26/2022 |
8-K
| Quarterly results |
| 09/28/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 09/02/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events ... |
| 08/26/2022 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 08/16/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/01/2022 |
DEL AM
| Form DEL AM - Delaying amendment: |
|
|
|